SNTI is trading at $1.04 (6.4%) down today. The decline follows its Q1 2026 earnings report, which was released last week, where: * Senti Biosciences reported a narrowed loss of -$0.36 EPS, beating analyst estimates. * The company highlighted the advancement of its SENTI-202 program into a pivotal phase. * Despite these updates, market sentiment reflects ongoing caution regarding the pre-commercial biotech's cash burn and clinical pipeline progress.